Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Apr 3

PMID 33809343

Citations 3

Authors

Anna Gliszczynska

Marta Nowaczyk

Affiliations

Soon will be listed here.

Abstract

Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy in relieving the symptoms of certain arthritis and in treating gout or collagen diseases, administration of IND causes a number of adverse effects, such as gastrointestinal ulceration, frequent central nervous system disorders and renal toxicity. These obstacles significantly limit the practical applications of IND and make that 10-20% of patients discontinue its use. Therefore, during the last three decades many attempts have been made to design novel formulations of IND aimed to increase its therapeutic benefits minimizing its adverse effects. In this review we summarize pharmacological information about IND and analyze its new lipid formulations and lipid bioconjugates as well as discuss their efficacy and potential application.

Citing Articles

Enhanced Stability and In Vitro Biocompatibility of Chitosan-Coated Lipid Vesicles for Indomethacin Delivery.

Abu Koush A, Popa E, Pricop D, Nita L, Foia C, Pauna A Pharmaceutics. 2025; 16(12.

PMID: 39771553 PMC: 11676990. DOI: 10.3390/pharmaceutics16121574.

Combination of Indomethacin with Nanostructured Lipid Carriers for Effective Anticancer Therapy.

Thiruchenthooran V, Espina M, Switalska M, Bonilla-Vidal L, Wietrzyk J, Garcia M Int J Nanomedicine. 2024; 19:7033-7048.

PMID: 39015675 PMC: 11249952. DOI: 10.2147/IJN.S464239.

Anti-Adhesive Resorbable Indomethacin/Bupivacaine-Eluting Nanofibers for Tendon Rupture Repair: In Vitro and In Vivo Studies.

Yu Y, Lee C, Hsu Y, Chou Y, Yu P, Huang C Int J Mol Sci. 2023; 24(22).

PMID: 38003425 PMC: 10671766. DOI: 10.3390/ijms242216235.

Antiulcer Activity of Anthraquinone-Flavonoid Complex of Losinsk.

Seitimova G, Shokan A, Tolstikova T, Zhukova N, Korulkin D, Kudrina N Molecules. 2023; 28(5).

PMID: 36903594 PMC: 10005188. DOI: 10.3390/molecules28052347.

References

Rosseto R, Hajdu J . Synthesis of oligo(ethylene glycol) substituted phosphatidylcholines: secretory PLA2-targeted precursors of NSAID prodrugs. Chem Phys Lipids. 2009; 163(1):110-6. PMC: 2927483. DOI: 10.1016/j.chemphyslip.2009.10.001. View

Somasundaram S, Hayllar H, Rafi S, Wrigglesworth J, Macpherson A, Bjarnason I . The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol. 1995; 30(4):289-99. DOI: 10.3109/00365529509093280. View

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520-8, 2 p following 1528. DOI: 10.1056/NEJM200011233432103. View

Dahan A, Duvdevani R, Dvir E, Elmann A, Hoffman A . A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J Control Release. 2007; 119(1):86-93. DOI: 10.1016/j.jconrel.2006.12.032. View

Guo Y, Chang C, Hsu W, Chiu S, Tsai Y, Chou Y . Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization. Molecules. 2013; 18(6):6584-96. PMC: 6269835. DOI: 10.3390/molecules18066584. View

McCall E, Youlten L . Proceedings: The effect of indomethacin and depletion of complement on cell migration and prostaglandin levels in carrageenin-induced air bleb inflammation. Br J Pharmacol. 1974; 52(3):452P. PMC: 1777018. View

Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley E, Siegert G . Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008; 10(3):279-86. PMC: 2259456. DOI: 10.1593/neo.07965. View

Griswold D, Adams J . Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev. 1996; 16(2):181-206. DOI: 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X. View

Brown W, Skinner S, Malcontenti-Wilson C, Vogiagis D, OBrien P . Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut. 2001; 48(5):660-6. PMC: 1728280. DOI: 10.1136/gut.48.5.660. View

10.

Wright J . The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002; 167(10):1131-7. PMC: 134294. View

11.

Lim Y, Phan T, Dial E, Graham D, Lichtenberger L . In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine. Digestion. 2012; 86(2):171-7. PMC: 3477857. DOI: 10.1159/000339882. View

12.

Pathan E, Gaitonde S, Rajadhyaksha S, Sule A, Mittal G, Joshi V . A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India. 2004; 51:1045-9. View

13.

Lichtenberger L . Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol. 2001; 61(6):631-7. DOI: 10.1016/s0006-2952(00)00576-1. View

14.

Pollard M, Luckert P . Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep. 1980; 64(12):1323-7. View

15.

Hunter L, Wood D, Dargan P . The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2016; 3:39-48. PMC: 4753966. DOI: 10.2147/OAEM.S22795. View

16.

McCulloch J, Kelly P, Grome J, Pickard J . Local cerebral circulatory and metabolic effects of indomethacin. Am J Physiol. 1982; 243(3):H416-23. DOI: 10.1152/ajpheart.1982.243.3.H416. View

17.

Carter G, Young P, SWETT L, PARIS G . Pharmacological studies in the rat with [2-(1,3-didecanoyloxy)-propyl]2-acetyloxybenzoate (A-45474): an aspirin pro-drug with negligible gastric irritation. Agents Actions. 1980; 10(3):240-5. DOI: 10.1007/BF02025942. View

18.

Waddell W, Gerner R, Reich M . Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol. 1983; 22(3):197-211. DOI: 10.1002/jso.2930220314. View

19.

Srinath P, Chary M, Vyas S, Diwan P . Long-circulating liposomes of indomethacin in arthritic rats--a biodisposition study. Pharm Acta Helv. 2000; 74(4):399-404. DOI: 10.1016/s0031-6865(00)00023-6. View

20.

Emori H, Champion G, Bluestone R, Paulus H . Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis. 1973; 32(5):433-5. PMC: 1006141. DOI: 10.1136/ard.32.5.433. View